Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

ClinicalTrials.gov ID: NCT00313768

Public ClinicalTrials.gov record NCT00313768. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Trial Of Paclitaxel, Carboplatin And Bevacizumab With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT00313768
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
23 participants

Conditions and interventions

Interventions

  • carboplatin + paclitaxel + bevacizumab + PF-3512676 Drug
  • paclitaxel + carboplatin + bevacizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2005
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008
Last update posted
Sep 27, 2009

2005 – 2008

United States locations

U.S. sites
29
U.S. states
9
U.S. cities
20
Facility City State ZIP Site status
Pfizer Investigational Site Bessemer Alabama 35022
Pfizer Investigational Site Birmingham Alabama 32511
Pfizer Investigational Site Birmingham Alabama 35205
Pfizer Investigational Site Birmingham Alabama 35209
Pfizer Investigational Site Birmingham Alabama 35213
Pfizer Investigational Site Birmingham Alabama 35235
Pfizer Investigational Site Mobile Alabama 36607
Pfizer Investigational Site Fountain Valley California 92708
Pfizer Investigational Site Los Angeles California 90033
Pfizer Investigational Site Cocoa Beach Florida 32931
Pfizer Investigational Site Merritt Island Florida 32952
Pfizer Investigational Site Rockledge Florida 32955
Pfizer Investigational Site Titusville Florida 32796
Pfizer Investigational Site Valdosta Georgia 31602
Pfizer Investigational Site Joliet Illinois 60432
Pfizer Investigational Site Joliet Illinois 60435
Pfizer Investigational Site Baltimore Maryland 21231
Pfizer Investigational Site Clinton North Carolina 28382
Pfizer Investigational Site Goldsboro North Carolina 27534
Pfizer Investigational Site Pollocksville North Carolina 28573
Pfizer Investigational Site Wilson North Carolina 27893
Pfizer Investigational Site Knoxville Tennessee 37920
Pfizer Investigational Site Knoxville Tennessee 37934
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Austin Texas 78745
Pfizer Investigational Site Austin Texas 78758
Pfizer Investigational Site Austin Texas 78759
Pfizer Investigational Site Georgetown Texas 78626
Pfizer Investigational Site San Marcos Texas 78666

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00313768, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 27, 2009 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00313768 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →